- Home
- PPBT vs ORIS Comparison
PPBT vs ORIS Comparison
Compare PPBT & ORIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PPBT
- ORIS
- Stock Information
- Founded
- PPBT 2010
- ORIS 2014
- Country
- PPBT Israel
- ORIS China
- Employees
- PPBT N/A
- ORIS N/A
- Industry
- PPBT Biotechnology: Pharmaceutical Preparations
- ORIS Farming/Seeds/Milling
- Sector
- PPBT Health Care
- ORIS Consumer Staples
- Exchange
- PPBT Nasdaq
- ORIS Nasdaq
- Market Cap
- PPBT 5.5M
- ORIS 5.3M
- IPO Year
- PPBT N/A
- ORIS 2024
- Fundamental
- Price
- PPBT $0.58
- ORIS $0.15
- Analyst Decision
- PPBT Strong Buy
- ORIS
- Analyst Count
- PPBT 1
- ORIS 0
- Target Price
- PPBT $33.00
- ORIS N/A
- AVG Volume (30 Days)
- PPBT 408.1K
- ORIS 45.4M
- Earning Date
- PPBT 11-14-2025
- ORIS 01-01-0001
- Dividend Yield
- PPBT N/A
- ORIS N/A
- EPS Growth
- PPBT N/A
- ORIS N/A
- EPS
- PPBT N/A
- ORIS 0.17
- Revenue
- PPBT N/A
- ORIS $15,014,000.00
- Revenue This Year
- PPBT N/A
- ORIS N/A
- Revenue Next Year
- PPBT N/A
- ORIS N/A
- P/E Ratio
- PPBT N/A
- ORIS $1.00
- Revenue Growth
- PPBT N/A
- ORIS N/A
- 52 Week Low
- PPBT $0.53
- ORIS $0.08
- 52 Week High
- PPBT $13.95
- ORIS $56.01
- Technical
- Relative Strength Index (RSI)
- PPBT 19.96
- ORIS 45.57
- Support Level
- PPBT $0.57
- ORIS $0.15
- Resistance Level
- PPBT $0.62
- ORIS $0.19
- Average True Range (ATR)
- PPBT 0.03
- ORIS 0.05
- MACD
- PPBT 0.06
- ORIS -0.01
- Stochastic Oscillator
- PPBT 45.09
- ORIS 5.47
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.
About ORIS Oriental Rise Holdings Limited Ordinary Shares
Oriental Rise Holdings Ltd is an integrated supplier of tea products in China. It is principally engaged in the business of planting, cultivating, processing, and selling processed tea. The company currently produces and sells three categories of products: roughly processed white tea, roughly processed black tea, and refined tea. The company's business operations are vertically integrated, covering cultivation, processing of tea leaves, and the sale of tea products to tea business operators and end-user retail customers. Geographically, the company generates all of its revenue from its business in the People's Republic of China (the PRC).